Changes in results of gallium-67-citrate scanning after interferon therapy for chronic hepatitis C

Journal of Nuclear Medicine

Volumn 38, Issue 2, 1997, Pages 216-219

  Shiomi, Susumu ^a   Kuroki, Tetsuo ^a   Yokogawa, Tadashi ^a   Takeda, Tadashi ^a   Nishiguchi, Shuhei ^a   Nakajima, Shinya ^a   Tanaka, Takashi ^a   Okamura, Terue ^a   Ochi, Hironobu ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

gallium 67 citrate; hepatitis C; interferon alpha; interstitial lung disease

Indexed keywords

ALPHA INTERFERON; GALLIUM CITRATE GA 67;

ADULT; AGED; ARTICLE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; INFLAMMATION; INTERSTITIAL LUNG DISEASE; LIVER BLOOD FLOW; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANTIVIRAL AGENTS; CITRATES; FEMALE; GALLIUM; HEPATITIS C; HEPATITIS, CHRONIC; HUMANS; INTERFERONS; LIVER; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED;

EID: 0031039213     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Hoofnagle JH, Peters M, Mullen KD, et al. Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B. Gastroenterology 1988;95:1318-1325.
2. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
3. Schultz M, Müller R, von zur Mühlen A, Brabant G. Induction of hyperthyroidism by interferon-α-2b. Lancet 1989;1:1452.
4. Chung Y-H, Shong YK. Development of thyroid autoimmunity after administration of recombinant human interferon-α-2b for chronic viral hepatitis. Am J Gastroenterol 1993;88:244-247.
5. Mayet W-J, Hess G, Gerken G, et al. Treatment of chronic type B hepatitis with recombinant α-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 1989;10:24-28.
6. Silva MO, Reddy KR, Jeffers LJ, Hill M, Schiff ER. Interferon-induced chronic active hepatitis? Gastroenterology 1991;101:840-842.
7. Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989;38:641-647.
8. Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992;340:548.
9. Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987;147:1577-1580.
10. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991;41:672-676.
11. 2 interferon-related cardiomyopathy. Am J Med 1988;85:549-551.
12. Sonnenblick M, Rosin A. Cardiotoxicity of interferon: a review of 44 cases. Chest 1991;99:557-561.
13. Chin K, Tabata C, Satake N, Nagai S, Moriyasu F, Kuno K. Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C. Chest 1994;105:939-941.
14. Kamitsukasa H, Ohtake M, Kawashima H, Yagura M, Harada H, Katayama T. Two cases of interstitial pneumonia induced by interferon therapy for chronic aggressive hepatitis, type C. Acta Hepatol Jpn 1993; 34:478-483 (in Japanese with English abstract).
15. Daito K, Suou T, Kawasaki H. A case of chronic hepatitis C with interstitial pneumonitis during interferon therapy. Acta Hepatol Jpn 1993; 34:718-722 (in Japanese with English abstract).
16. Yamamoto S, Shimabara M, Yamamoto R, et al. A case of chronic hepatitis C with pneumonitis during interferon therapy. Nippon Shokakibyo Gakkai Zasshi 1993;90: 2142-2146 (in Japanese).
17. Crystal RG, Fulmer JD, Roberts WC, Moss ML, Line BR, Reynolds HY. Idiopathic pulmonary fibrosis: clinical, histologic, radiographic, physiologic, scintigraphic, cytologic and biochemical aspects. Ann Intern Med 1976;85:769-788.
18. Niden AH, Mishkin FS, Khurana MML. Gallium-67-citrate lung scans in interstitial lung disease. Chest 1976;69(suppl):266-268.
19. Scheuer PJ, Thaler H, Desmet VJ, et al. Acute and chronic hepatitis revisited: review by an international group. Lancet 1977;2:914-919.
20. DeGroote J, Desmet VJ, Gedigk P, et al. A classification of chronic hepatitis. Lancet 1968;2:626-628.
21. Tzen K-Y, Oster ZH, Wagner HN Jr, Tsan M-F. Role of iron-binding proteins and enhanced capillary permeability on the accumulation of gallium-67. J Nucl Med 1980;21:31-35.
22. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051-1055.
23. Siemsen JK, Grebe SF, Sargent EN, Wentz D. Gallium-67 scintigraphy of pulmonary diseases as a complement to radiography. Radiology 1976;118:371-375.
24. 67Ga-citrate. J Nucl Med 1973;15:227-233.
25. Swartzendruber DC, Nelson B, Hayes RL. Gallium-67 localization in lysosomal-like granules of leukemic and nonleukemic murine tissues. J Natl Cancer Inst 1971;46: 941-952.
26. Line BR, Fulmer JD, Reynolds HY, et al. Gallium-67-citrate scanning in the staging of idiopathic pulmonary fibrosis: correlation with physiologic and morphologic features and bronchoalveolar lavage. Am Rev Respir Dis 1978;118:355-365.
27. Cooper JAD Jr, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: cytotoxic drugs. Am Rev Respir Dis 1986;133:321-340.
28. Cooper JAD Jr, White DA, Matthay RA. Drug-induced pulmonary disease. Part 2: noncytotoxic drugs. Am Rev Respir Dis 1986;133:488-505.
29. Roth JA, Frank DE. Recombinant bovine interferon-γ as an immunomodulator in dexamethasone-treated and nontreated cattle. J Interferon Res 1989;9:143-151.
30. Ueda T, Ohta K, Suzuki N, et al. Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis 1992;146:266-268.